Abstract: The present disclosure provides methods of treatment of neurodegenerative disease in subjects in need thereof. A therapeutically effective dose of combination of a suitable mast cell stabilizer and NSAID may be administered to suitable subjects, wherein the suitability of a subject is determined by subject genotype. In certain embodiments, the combination therapy may comprise a combination of a cromolyn homolog salt and an NSAID, and suitable subjects are persons who are not carriers APOE ?4 variant of the APOE gene.

Abstract: This invention relates to dual activity compounds and uses thereof for the treatment of type 2 diabetes in patients who are overweight or obese.

Abstract: Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.

Abstract: Described herein are compounds and methods of treating a disease or disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of a cromolyn ester.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2 , or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein: X is OH, C1-C6 alkoxyl; Y and Z are independently selected form a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Abstract: The invention is directed to a composition comprising cromolyn sodium and ibuprofen, wherein the cromolyn sodium is micronized and the cromolyn sodium and ibuprofen are present in a weight ratio of 1:1-2. In one embodiment, the ibuprofen is passed through a sieve, such as a 300 ?m sieve and to methods of making the same.

Abstract: Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and packs and kits comprising cromolyn are described.

Abstract: The present disclosure relates to a pharmaceutical composition, such as a dry powder inhalation formulation or an injectable formulation, comprising a mixture of an antiviral agent and a mast cell stabilizer. The present disclosure relates to a codrug comprising a residue of an antiviral agent covalently bonded via a labile bond to a residue of a compound of Formula (I) or Formula (II). The present disclosure further relates to a method of administering an antiviral agent and a Formula I/II compound, a pharmaceutical composition, or a codrug to treat coronavirus infection and/or associated inflammation.

Abstract: Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.

Abstract: A single or multi layered device (hereinafter alternately referred to as a “capsule”) of non-digestible material encapsulating an ingestible drug solution capable of slow solution release of stable solubilized drugs in water, saline, a buffer or lipophilic acceptable carriers. Methods for preparing the same and for safe, nearly constant dispensing of drugs following capsule swallowing. A safe, controlled flow release mechanism for the capsule's drug to the gastric system is disclosed.

Abstract: Described herein are self-assembling protein molecules for delivering a payload, for example, a toxic anti-cancer agent, a cancer immunotherapy, a toxic anti-cancer agent and a cancer immunotherapy, or an imaging agent, to specific tissues. Examples of self-assembled proteins include clathrin and derivatives of clathrin.

Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.

Abstract: The present disclosure relates to a method of treating one or more inflammation conditions induced by a coronavirus infection in a subject in need thereof, comprising administering a pharmaceutical composition comprising a compound of Formula I or Formula II, wherein R1 is halogen, OH, or —OC(O)C1-5alkyl, R2 and R3 are each independently selected from CO2R4 and CH2OR5; R4 is Li, Na, K, H, C1-5-alkyl, or —CH2CO(C1-5alkyl); and R5 is H or —C(O)(C1-5alkyl), or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to various clathrin constructs for immune cell activation in vivo. The present invention also relates to the use of various clathrin constructs for the detection or treatment of tumors, cancers, or other diseases or physiological condition. Disclosed herein are chimeric protein constructs including: a clathrin protein moiety; a chimeric antigen receptor (CAR) including: an ectodomain having an antigen binding domain; a transmembrane domain; and an endodomain having an intracellular signaling domain. Also disclosed herein are methods of producing a chimeric antigen receptor (CAR)-engineered cell of interest for in vivo activation of T-cells, B-cells and T-Reg cell, as well as others for inhibiting the growth, mutagenesis, or metastasis of a cancer, a tumor, or other neoplasm in a subject and methods of obtaining an image of a target cell of interest in a subject.

Abstract: A dispenser for dispensing one or more dry-powder inhaler devices, having at least one compartment configured to hold at least one dry-powder inhaler device, the at least one dry-powder inhaler device comprising a casing enclosing at least one compartment containing an inhalable medicament covered by a cover, and at least one puncture mechanism comprising at least one pin structure operably aligned with the at least one compartment, and at least one obstruction internally located within the dispenser and adjacent to an opening, wherein, upon a dry-powder inhaler device being pulled from a dispenser, the at least one obstruction is configured to actuate the at least one puncture mechanism to extend the at least one pin structure into the casing, thereby puncturing the cover of the at least one compartment.

Abstract: The present disclosure relates to a method of treating at least one Cell-Associated Neurotoxicity Syndrome (ICANS), cancer-related cognitive impairment, Infusion Reaction Syndrome (IRS), Capillary Leak Syndrome (CLS), Tumor Lysis Syndrome (TLS), Macrophage Activation Syndrome (MAS), Systemic Inflammatory Response Syndrome (SIRS), Immune Reconstitution Inflammatory Syndrome (IRIS), Graft-Versus-Host Disease (GVHD), Acute Respiratory Distress Syndrome (ARDS), sepsis, Ebola, avian influenza, smallpox, Systemic Inflammatory Response Syndrome (SIRS), and Immune-related Adverse Events Syndrome (IrAES) in a subject in need thereof, comprising administering a mast cell stabilizer or a compound of Formula I or Formula II: Formula I, Formula II, wherein R1 is halogen, OH, or —OC(O)C1-5alkyl R2 and R3 are each independently selected from CO2R4 or CH2OR5; R4 is i L, Na, K, H, C1-5alkyl, or —CH2CO(C1-5alkyl); and R5 is H or C(O)(C1-5alkyl), or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

Abstract: The invention is directed to methods of treating ischemic stroke by administering a therapeutically effective amount of at least one compound of Formula I or Formula II to a subject in need thereof, wherein the compound has Formula I or Formula II: or a salt or ester of (I) or (II); wherein X is OH, C1-C6 alkoxyl, 18F, or 19F; Y and Z are independently selected from C1-C6 alkyl, C1-C6 alkoxyl, halogen, substituted or unsubstituted C1-C6 amine, 18F, 19F, or H; and n is 1, 2, or 3.

Abstract: The present disclosure is directed to a composition comprising micronized cromolyn sodium, ?-lactose, and a salt of fatty acid, wherein the ?-lactose has a particle size distribution of D90 of 45-70 ?m, D50 of 10-35 ?m, and D10 of 2-13 ?m. The present disclosure is also directed to a method of treating Alzheimer's disease, amyloidosis-associated condition (AAC), traumatic brain injury, Huntington's disease, atherosclerosis, cytokine release syndrome (CRS), dementia, head injury, infection, neuroinflammation, prion disease, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, or asthma using the composition.